In DN and metabolic disease, genotype-dependent responses linked to ACE I/D, eNOS, and SOD2 polymorphisms complicate drug selection, while non-vasodilating BBs can exacerbate insulin resistance and dyslipidemia. The gene discussed is SOD2; the disease is metabolic syndrome.